White Paper i Driving A Data Strategy Initiative Learn More White Paper i Data-Driven Customer Journey Design Using Bayesian Network Methodology Learn More Roundtable i Pharma Omnichannel Trends In A Post-COVID World Learn More Report i HEOR Value Demonstration and Evidence Generation Challenges Learn More White Paper i Do Pharma Companies Need To Rethink Their Sales Operations Design? Learn More White Paper i What Analytical Techniques Should Pharma Companies Implement To Forecast COVID-19 Effects? Learn More White Paper i Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning Learn More White Paper i COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes Learn More White Paper i Coronavirus Pandemic Effects On Incentive Compensation Learn More White Paper i Designing A Patient-Centric Commercial Strategy Learn More White Paper i How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry? Learn More White Paper i Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry? Learn More White Paper i One Important Lesson From Biogen’s Surprise Announcement On Hopes For An Alzheimer’s Drug Learn More White Paper i Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary Learn More White Paper i Pharma’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy Learn More White Paper i How Will The Next Great Recession Affect The US Pharma Industry? Learn More White Paper i Future Of Pharma: Evolving Commercial Models – Part 2 Learn More White Paper i Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value? Learn More White Paper i Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program Learn More Report i Future Of Pharma: Evolving Commercial Models – Part 1 Learn More White Paper i Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs Learn More Report i How Regulatory Changes Are Driving The Future Of The Medical Device Industry Learn More White Paper i Growing Attention Being Paid To Pharma Company Rebates And Discounts Learn More White Paper i Perspectives On Pharma Company Use Of Open Payments Data Learn More White Paper i Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US Learn More White Paper i The recent woes of non-bank mortgage servicers Learn More White Paper i Account-based models in an institutional setting Learn More White Paper i From “sick” care to “health” care: analytics-driven transformation Learn More White Paper i Effective Quality Assurance For Banks Learn More White Paper i Telematics – Watching Your Every Move Learn More White Paper i Payer Influence On Product Performance In Pharmaceutical Industry Learn More White Paper i Mortgage Servicer – You’ve Got Information! Learn More White Paper i Operational Risk Computation Methodology Learn More White Paper i Improve STAR Rating With Analytics Powered Therapy Adherence Strategy Learn More White Paper i Is Channel ROI Dead? Learn More Article i Risk Basel Methodology Implementation Learn More White Paper i Linking Customer Focus With Business Performance Learn More White Paper i Enabling Smarter Commercial Model Experimentation Learn More Article i Claim Operations Optimization Learn More White Paper i Portfolio Stress Testing Methodologies Learn More White Paper i Evolution Of SDLC Learn More White Paper i Behavioural Segment Based Stress Testing Using Markov Chain Learn More White Paper i Borrower Centrism – Bring ‘Service’ Back Into Mortgage Servicing Learn More White Paper i Basel Downturn – Identification & Estimation Learn More White Paper i Operational Risk Management In Banks Learn More White Paper i A Mathematical Framework For Privacy Risk Learn More White Paper i Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems Learn More White Paper i At Supplier Management Crossroads? – Choose The Right Approach Learn More White Paper i Driver Score – The New Paradigm Learn More White Paper i The Pricing Challenge Of Pharma’s Shift To Specialty Medicines Learn More White Paper i Measuring Sales Rep-Physician Relationship Disruption In Sales Force Optimization & Territory Alignment Learn More White Paper i Biosimilars In The US – Will They Deliver On The Promise? Learn More Article i Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization Learn More Article i Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics Learn More White Paper i The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment Learn More White Paper i The Relationship Between Drug Price Controls And Patient Health Outcomes Learn More White Paper i Patient Claims Versus EHR Data – How To Choose Between The Two? Learn More White Paper i Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far? Learn More White Paper i Econometric Analysis Of Biopharmaceutical Transfer Pricing Learn More Blog i Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics Learn More White Paper i Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies Learn More White Paper i Is it Time to Adjust the Pharma PDE Sales Force Optimization Model? Learn More Report i State Of Commercial Excellence 2017 – Part 1 Learn More Article i Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues Learn More White Paper i Pricing and Market Effects of Biosimilar Entry in the US Learn More White Paper i The Reasons for and Solutions to Chronic Drug Shortages in the United States Learn More White Paper i Decision Science Asset Diversification Versus Concentration Learn More White Paper i Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes Learn More White Paper i Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary Learn More White Paper i The Causes and Solutions of Chronic Drug Shortages in the United States Learn More White Paper i Insightful HEOR Analysis For The Cardiovascular Community Learn More Blog i Quantifying The Economic Burden Of Inadequate Symptom Control Among Patients With IBS-D Learn More White Paper i Quantifying The Economic Burden Of IBS-D Learn More